NCT05802927CompletedNot Applicable
A Randomized Controlled Trial to Determine the Effects of Diabetes-specific Formula on Glycemic Control in Individuals With Type 2 Diabetes
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Abbott Nutrition
- Enrollment
- 64
- Locations
- 2
- Primary Endpoint
- Postprandial blood glucose
Study Overview
Brief Summary
A randomized, controlled, crossover design with three treatments to determine the effects of diabetes-specific formula on glycemic control in individuals with type 2 diabetes.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 21 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •Has type 2 diabetes as evidenced by use of oral antihyperglycemic medication(s).
- •BMI > 18.5 and ≤ 35.0 kg/m
- •Weight stable.
- •Male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit.
- •If on chronic medication, the dosage to be constant for at least two months prior to screening visit and to maintain the medication and dose throughout the study.
- •Willing to follow the protocol throughout the study.
- •At least a two-week washout period between completion of a previous research study and their start in the current study.
- •Willing to refrain from taking non-study diabetes-specific formulas over the course of the study.
- •Voluntarily signed and dated an Informed Consent Form (ICF) prior to any participation in the study.
Exclusion Criteria
- •Participants are excluded from the study if any of the following criteria apply:
- •Has a screening HbA1c level < 7% or ≥ 10%.
- •Uses exogenous insulin for glucose control.
- •Has confirmed type 1 diabetes and/or had history of diabetic ketoacidosis.
- •Has current infection, inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or received antibiotics in the last 3 weeks.
- •Has active malignancy.
- •Has significant cardiovascular event within 6 months prior to study entry or history of congestive heart failure.
- •Has end stage organ failure or was post organ transplant.
- •Has a history of renal disease or severe gastroparesis.
- •Has current hepatic disease.
- •Has had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery that can interfere with consumption or digestion or absorption of study product.
- •Has a chronic, contagious, infectious disease.
- •Has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.
- •Taking any herbals, dietary supplements or medications other than allowed anti-hyperglycemic medications, during the past four weeks prior to screening visit that could profoundly affect blood glucose or appetite.
- •Uses diabetes-specific formula(s) defined as more than one eating occasion per week in the last three months.
- •Has clotting or bleeding disorders.
- •Participates in another study that has not been approved as a concomitant study by Abbott Nutrition.
- •Has allergy or intolerance to any ingredient in the study product.
Arms & Interventions
Experimental: Breakfast 2 Glutinous rice
Other
Intervention: Breakfast 2 (Other)
Experimental: Diabetes-specific formula
Other
Intervention: DSF (Other)
Experimental: Breakfast 1 Noodle Soup
Other
Intervention: Breakfast 1 (Other)
Outcomes
Primary Outcomes
Postprandial blood glucose
Time Frame: 3 hours
Positive area under the curve (AUC) for blood glucose concentration from 0 to 180 minutes.
Secondary Outcomes
- Postprandial insulin(3 hours)
- Appetite(3 hours)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System in the Healing of Diabetic Foot UlcersDiabetic Foot UlcerNCT05519501Syntr Health Technologies, Inc.62
Completed
Not Applicable
Diabetes-Specific Formula in Individuals With Type 2 DiabetesDiabetes Mellitus, Type 2NCT04303754Abbott Nutrition100
Completed
Not Applicable
Evaluation of Glycemic Response in Individuals With Type 2 DiabetesGlycemic ControlNCT05165693Abbott Nutrition24
Completed
Not Applicable
Glycemic Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes MellitusDiabetesNCT02856516Société des Produits Nestlé (SPN)12
Completed
Not Applicable
To Assess the Efficacy of Investigational Product on the Neuropathic Pain in Individuals Suffering From Type II Diabetes Mellitus.Diabetic NeuropathiesInsomnia Due to Medical ConditionNCT04504305Vedic Lifesciences Pvt. Ltd.64